An observational study in Hypertension, Blood Pressure Monitoring and Wearable Devices, sponsored by Technische Universität Dresden. Recruiting at 2 sites in 2 countries. Open to participants aged 21 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-26.
Sponsored by Technische Universität Dresden · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 282 studies in Hypertension with a site in Germany — 29 open to participants now, 46 under way, 11 of them phase 3. Hypertension · Germany.
Among the 282 studies in Hypertension with a site in Germany, this one is the 15th largest by planned enrollment of the 30 observational ones that give a count, is one of 5 that started in 2026, is one of 31 observational ones, reaches primary completion later than 29 of the 45 other live ones, and was the 280th registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →29 of the 282 studies in Hypertension with a site in Germany are open now. Recruiting first, the newest first:
Universitätsklinikum Hamburg-Eppendorf · Sites in Germany
Ages 18+
Prof. Dr. med. Ingo Eitel · Sites in Germany
Ages 60+
University of Erlangen-Nürnberg Medical School · Sites in Germany
Ages 18–75 · Healthy volunteers
Medtronic Vascular · Sites in Germany, Australia, Belgium and 6 more countries
Ages 18+
Alnylam Pharmaceuticals · Sites in Germany, United States, Argentina and 32 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 21 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
282 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 29 · Phase 3 125 · Phase 4 26
First in 1998; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is below the median of 352 across 1,166 observational studies indexed under Hypertension.
Median enrollment 200 across the 250 interventional studies, 120 across the 30 observational. Of the 219 that completed or were terminated, 81 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
200 of 282 have an industry lead sponsor. The 10 most frequent:
Technische Universität Dresden is the lead sponsor of 247 studies on the registry; 46 are open to participants now.
Technische Universität Dresden has 1 study filed under Hypertension — fewer than ten, so there is no comparison to draw.
20 of the studies in Hypertension with a site in Germany that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT06948422Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) | 2027-09 |
| NCT06948435Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 | 2027-09 |
| NCT06952530Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2 | 2027-09 |
| NCT03604198Corcept TherapeuticsExtension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome | 2026-12 |
Add all 20 to your calendar (.ics) → With an account.
Among the 282 studies in Hypertension with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to compare the accuracy, clinical applicability, and usability of different wearable blood pressure monitoring methods integrated in wearable devices, such as smartwatches, in hospitalized patients. The study evaluates novel photoplethysmography (PPG)-based and wrist-oscillometric blood pressure measurement methods against established clinical reference methods (upper-arm cuff measurements on the general ward and invasive arterial blood pressure monitoring (A-line) in the intensive care unit).
The main questions the study aims to answer are:
To answer these questions, participants will undergo:
Hospitalized adult patients aged 21 to 85 years who are treated on participating general wards or intensive care units at the hospital and are able to provide written informed consent.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Agreement of wearable blood pressure measurement methods with clinical reference measurements
The mean difference and standard deviation of the differences in systolic and diastolic blood pressure, expressed in mmHg, between each investigated wearable blood pressure measurement method and the corresponding reference method.
Time frame: General ward: At each measurement session on study days 1, 2, and 3. ICU: At measurement session on study day 1, approx. 2 hours after device calibration
Plan to share: Yes — We plan to provide the anonymized IPD after publication.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: after finishing the study, data will be stored locally for at least 10 years
Access criteria: contact the investigators via mail
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Jul 2027, 12 months after the start.
Of 348 non-industry observational studies under Hypertension, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 111. This study's planned 12 months is below that.
Counting every sponsor, half of 429 studies reached it within 38 months; a quarter within 17 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Technische Universität Dresden →